The content should be medically relevant and adhere docstop content guidelines . Docstop doesn’t support any brand related promotional activities

Share articles, case studies and web videos

Method : start a topic- select private, add group, give name, add email ids, and send to your selected group


22 May | Categories : Oncology Start a topic Comment Mail Share Download
Exploring the Advancements in Primary Healthcare conferences 2021 Paris, France organised by Pencis.

Cardiology Primary Care | Dental Science Primary Care |Diabetes & Primary Care |Emergency Healthcare Medicine |Family Medicine & Primary Care |Fitness and Wellness & Primary Care |Global Primary Care |Health Economics |Healthcare & Primary Care |Major Challenges |Management and Primary Care |Mental Health & Primary Care |Nursing & Primary Care |Nutrition & Primary Care |Oncology & Primary Care |Pediatrics & Primary Care |Primary Care Epidemiology & Primary Care |Primary Home Care  |Public Health & Primary Care

">


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download
Background

Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19.

Methods

This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group). The primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population. The study is registered with ClinicalTrials.govNCT04276688.

Findings

Between Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group. The median number of days from symptom onset to start of study treatment was 5 days (IQR 3–7). The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5–11]) than the control group (12 days [8–15]; hazard ratio 4·37 [95% CI 1·86–10·24], p=0·0010). Adverse events included self-limited nausea and diarrhoea with no difference between the two groups. One patient in the control group discontinued lopinavir–ritonavir because of biochemical hepatitis. No patients died during the study.

">


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download


4 May | Categories : Orthopedics Start a topic Comment Mail Share Download
ReadMore ">


4 May | Categories : Orthopedics Start a topic Comment Mail Share Download
ReadMore

">


4 May | Categories : Orthopedics Start a topic Comment Mail Share Download
ReadMore

">